JP6902018B2 - キメラ抗原受容体及び他の受容体の発現に対するt細胞 - Google Patents
キメラ抗原受容体及び他の受容体の発現に対するt細胞 Download PDFInfo
- Publication number
- JP6902018B2 JP6902018B2 JP2018502699A JP2018502699A JP6902018B2 JP 6902018 B2 JP6902018 B2 JP 6902018B2 JP 2018502699 A JP2018502699 A JP 2018502699A JP 2018502699 A JP2018502699 A JP 2018502699A JP 6902018 B2 JP6902018 B2 JP 6902018B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- cell
- cd62l
- isolated human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 207
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims description 49
- 102000005962 receptors Human genes 0.000 title description 4
- 108020003175 receptors Proteins 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 341
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 71
- 102100033467 L-selectin Human genes 0.000 claims description 71
- 210000005260 human cell Anatomy 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 48
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 40
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 20
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 20
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 19
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 19
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 230000000779 depleting effect Effects 0.000 claims description 8
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 7
- 108091008874 T cell receptors Proteins 0.000 claims description 7
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000047 product Substances 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 24
- 238000000684 flow cytometry Methods 0.000 description 24
- 230000026683 transduction Effects 0.000 description 22
- 238000010361 transduction Methods 0.000 description 22
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 20
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 20
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 17
- 239000011324 bead Substances 0.000 description 16
- 239000003550 marker Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 241000713666 Lentivirus Species 0.000 description 13
- 239000012636 effector Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108090000176 Interleukin-13 Proteins 0.000 description 9
- 102000003816 Interleukin-13 Human genes 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 102100027207 CD27 antigen Human genes 0.000 description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 6
- 210000004460 N cell Anatomy 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 5
- 241000021375 Xenogenes Species 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 230000001461 cytolytic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000019207 human interleukin-13 Human genes 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
様々な方法を使用して、ヒトTCM/SCM/N細胞の集団を生成することができる。例えば、TCM/SCM/N細胞の集団を、混合Tリンパ球集団から調製することができる。Tリンパ球の集団は、細胞を使用して最終的に処置された対象に対して同種異系又は自己由来であり得、さらに、白血球フェレーシス又は採血によって対象から得ることができる。
1)CD62L+セントラルメモリー(TCM)細胞、及び、2)セントラルメモリー(TCM)集団も幹細胞様メモリー(TSCM)集団も、ナイーブT細胞(TN)と共に含むCD62L+TCM/SCM/N細胞のT細胞集団のCliniMACS/AutoMACS(商標)による濃縮を受けたヒト末梢血単核細胞(PBMC)の収率を評価するために研究を行った。生細胞数のGuava分析及び表現型のフローサイトメトリー分析を使用して評価を行った。
TCM/SCM/N細胞集団は、関心のある1つ又は複数のタンパク質を発現するように遺伝子操作することができる。例えば、細胞を、関心のある1つ又は複数のタンパク質を発現する能力を持つレンチウイルスで形質導入することができる。以下は、硫酸プロタミン/サイトカイン溶液を用いてレンチウイルスベクターでT細胞を形質導入するために使用することができる1つの方法の例である。
CD62L+TCMの集団又はCD62L+TCM/SCM/Nの集団(ナイーブ、セントラルメモリー及び幹細胞様メモリーのT細胞を含む)のいずれかについて、CliniMACS/AutoMACS(商標)による濃縮を受け、その後、臨床的使用のために提案された方法を使用してビーズ刺激、及び、CD19Rを標的とするCARを発現するレンチウイルスであるCD19R(EQ)28Z−T2A−EGFRt_epHIV7又はIL−13Ralplaを標的とするレンチウイルスベクターであるIL13(EQ)BBZ−T2A−CD19t_epHIV7でレンチウイルス形質導入を行ったヒト末梢血単核細胞(PBMC)のex vivoでの増殖及び細胞表面表現型を評価するために研究を行った(ベクター及び発現したCARの詳細については特許文献1及び特許文献3を参照)。生細胞数のモニタリングによって増殖を評価し、さらに、フローサイトメトリー分析によって細胞表面表現型を評価した。
臨床的使用に適した方法を使用して、CD19を標的としたCARを発現するレンチウイルスベクター(CD19R(EQ)28Z−T2A−EGFRt_epHIV7レンチウイルスベクター)で形質導入し且つ増殖させた選択されていないPBMC、CD62L+TCM細胞及びCD62L+TCM/SCM/N細胞のin vivoでの有効性を評価するために、研究を行った。静脈内(iv)投与されたこれらの細胞のin vivoでの抗腫瘍の有効性を、緑色蛍光タンパク質(GFP)及びホタルルシフェラーゼ(ffLuc)レポーター遺伝子を発現するように操作されたCD19発現SUP−B15ヒト急性リンパ球性白血病の細胞株を使用して、免疫不全のNSGマウスにおいて調べた(PMID:22407828)。
臨床的使用に適していると予想される方法を使用して、CD19R(EQ)28Z−T2A−EGFRt_epHIV7レンチウイルスベクターで形質導入し且つ増殖させたCD62L+セントラルメモリー(TCM)細胞又はCD62L+TCM/SCM/N細胞のCD19特異的な細胞溶解活性、脱顆粒及びサイトカイン生成を評価するために、研究を行った。細胞溶解活性を、フローサイトメトリーに基づく長期の死滅アッセイ及び5時間の脱顆粒アッセイを使用して評価した。サイトカイン生成を、刺激細胞との5時間の共培養後に、T細胞の細胞内染色によって評価した。
IL13Rα2を標的とするCARを発現するレンチウイルスベクターで形質導入したCD62L+TCM細胞及びCD62L+TCM/SCM/N細胞のin vivoでの有効性を評価するために、研究を行った。CARは、ヒトIL−13変異体を含み、レンチウイルスベクター(IL13(EQ)BBZ−T2A−CD19t_epHIV7)によって発現される。このベクターを発現する細胞集団を実施例4において先に記載したように調製し、ホタルルシフェラーゼ(ffLuc)レポーター遺伝子を発現するように操作されたIL13Rα2+初代低継代GBM腫瘍様塊の株PBT030−2を使用した免疫不全NSGマウスにおける神経膠芽腫のマウスモデルにおいて評価した。
Claims (28)
- T細胞を含む単離されたヒト細胞の集団であって、前記T細胞は、セントラルメモリーT細胞、幹細胞様メモリーT細胞及びナイーブT細胞を含み、前記T細胞のうち50%を超えるT細胞がCD45RA+であり、さらに、前記T細胞のうち70%を超えるT細胞がCD62L+であり、前記T細胞のうち15%未満がCD14+であり、さらに、前記T細胞のうち5%未満がCD25+であり、かつ、前記T細胞のうち25%を超えるT細胞が組換え核酸分子を宿す、単離されたヒト細胞の集団。
- 前記組換え核酸分子はウイルスベクターである、請求項1に記載の単離されたヒト細胞の集団。
- 前記組換え核酸分子はキメラ抗原受容体をコードする、請求項1に記載の単離されたヒト細胞の集団。
- 前記組換え核酸分子はT細胞受容体をコードする、請求項1に記載の単離されたヒト細胞の集団。
- 前記T細胞のうち少なくとも70%が、CD4+及びCD62L+、又は、CD8+及びCD62L+である、請求項1に記載の単離されたヒト細胞の集団。
- 前記T細胞のうち60%未満がCD45RO+である、請求項1に記載の単離されたヒト細胞の集団。
- T細胞を含む単離されたヒト細胞の集団であって、前記T細胞は、セントラルメモリーT細胞及び幹細胞様メモリーT細胞を含み、前記T細胞のうち50%を超えるT細胞がCD45RA+であり、前記T細胞のうち70%を超えるT細胞がCD62L+であり、前記T細胞のうち85%を超えるT細胞がCD95+であり、さらに、前記T細胞のうち25%を超えるT細胞が組換え核酸分子を宿す、単離されたヒト細胞の集団。
- 前記組換え核酸分子はウイルスベクターである、請求項7に記載の単離されたヒト細胞の集団。
- 前記組換え核酸分子はキメラ抗原受容体をコードする、請求項7に記載の単離されたヒト細胞の集団。
- 前記組換え核酸分子はT細胞受容体をコードする、請求項7に記載の単離されたヒト細胞の集団。
- 前記T細胞のうち少なくとも70%が、CD4+及びCD62L+、又は、CD8+及びCD62L+である、請求項7に記載の単離されたヒト細胞の集団。
- 前記T細胞のうち60%未満がCD45RO+である、請求項7に記載の単離されたヒト細胞の集団。
- 組換え核酸分子を宿すT細胞を含むヒト細胞の集団を調製する方法であって、
(a)T細胞を含むヒト細胞の集団を提供するステップであり、前記T細胞は、セントラルメモリーT細胞、幹細胞様メモリーT細胞及びナイーブT細胞を含み、前記T細胞のうち50%を超えるT細胞がCD45RA+であり、さらに、前記T細胞のうち70%を超えるT細胞がCD62L+である、ステップ、
(b)前記T細胞を含むヒト細胞の集団を活性化するステップ、及び、
(c)前記T細胞を含むヒト細胞の集団内の細胞に、組換え核酸分子を形質導入又は遺伝子導入して、組換え核酸分子を宿すT細胞を含むヒト細胞の集団を提供するステップ、
を含み、
CD45RAを発現する細胞を枯渇させるステップを含まない方法。 - 前記組換え核酸分子はウイルスベクターである、請求項13に記載の方法。
- 前記組換え核酸分子を宿すT細胞を含むヒト細胞の集団を培養するステップをさらに含む、請求項13に記載の方法。
- 前記培養するステップは、外来性IL−2及び外来性IL−15の添加を含む、請求項15に記載の方法。
- 前記活性化するステップは、抗CD3抗体及び抗CD28抗体に前記細胞を曝露するステップを含む、請求項13に記載の方法。
- 前記ウイルスベクターは、キメラ抗原受容体又はT細胞受容体をコードするヌクレオチド配列を含むレンチウイルスベクターである、請求項14に記載の方法。
- T細胞を含むヒト細胞の集団を調製する方法であって、前記T細胞は、セントラルメモリーT細胞、幹細胞様メモリーT細胞及びナイーブT細胞を含み、前記細胞のうち50%を超える細胞がCD45RA+であり、さらに、前記細胞のうち70%を超える細胞がCD62L+であり、当該方法は、
(a)T細胞を含むヒト細胞の試料を提供するステップ、
(b)枯渇した細胞集団を調製するために、CD25を発現する細胞、及び、CD14を発現する細胞を枯渇させるように前記T細胞を含むヒト細胞の試料を処理するステップ、
及び、
(c)CD62Lを発現する細胞を濃縮するように前記枯渇した細胞集団を処理し、その結果、T細胞を含むヒト細胞の集団を調製するステップであり、前記T細胞は、セントラルメモリーT細胞、幹細胞様メモリーT細胞及びナイーブT細胞を含み、前記細胞のうち50%を超える細胞がCD45RA+であり、さらに、前記細胞のうち70%を超える細胞がCD62L+である、ステップ、
を含み、
CD45RAを発現する細胞を枯渇させるステップを含まない方法。 - 前記T細胞を含むヒト細胞の集団を活性化するステップ、及び、前記活性化された細胞に、組換え核酸分子を形質導入又は遺伝子導入して、組換え核酸分子を宿すT細胞を含むT細胞の集団を提供するステップをさらに含む、請求項19に記載の方法。
- T細胞を含むヒト細胞の試料はPBMCを含む、請求項19に記載の方法。
- 請求項1〜12のいずれか一項に記載のT細胞を含む、単離されたヒト細胞の集団を含む、癌、自己免疫又は感染を治療するための医薬組成物。
- 前記単離されたヒト細胞の単離された集団は、それが必要な患者に対して自己由来である、請求項22に記載の医薬組成物。
- 前記単離されたヒト細胞の単離された集団は、それが必要な患者に対して同種異系である、請求項22に記載の医薬組成物。
- T細胞を含む単離されたヒト細胞の集団であって、前記T細胞は、セントラルメモリーT細胞、幹細胞様メモリーT細胞及びナイーブT細胞を含み、前記T細胞のうち50%を超えるT細胞がCD45RA+であり、さらに、前記T細胞のうち70%を超えるT細胞がCD62L+であり、前記集団は、T細胞を含むヒト細胞の試料を提供するステップ、
枯渇した細胞集団を調製するために、前記試料を抗CD14抗体及び抗CD25抗体に接触させることにより、CD25を発現する細胞を枯渇させ、かつ、CD14を発現する細胞を枯渇させるように前記T細胞を含むヒト細胞の試料を処理するステップ、及び、CD62Lを発現する細胞を濃縮するように前記枯渇した細胞集団を処理し、その結果、T細胞を含む単離されたヒト細胞の集団を調製するステップであり、前記T細胞は、セントラルメモリーT細胞、幹細胞様メモリーT細胞及びナイーブT細胞を含み、前記細胞のうち40%を超える細胞がCD45RO+であり、さらに、前記細胞のうち70%を超える細胞がCD62L+である、ステップを含み、CD45RAを発現する細胞を枯渇させるステップを含まない方法によって調製される、単離されたヒト細胞の集団。 - 前記T細胞のうち15%未満がCD14+であり、さらに、前記T細胞のうち5%未満がCD25+である、請求項25に記載の単離されたヒト細胞の集団。
- 前記T細胞のうち少なくとも70%が、CD4+及びCD62L+、又は、CD8+及びCD62L+である、請求項1に記載の単離されたヒト細胞の集団。
- 前記T細胞のうち60%未満がCD45RO+である、請求項1に記載の単離されたヒト細胞の集団。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021101244A JP7242761B2 (ja) | 2015-07-21 | 2021-06-18 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
JP2023035590A JP2023076471A (ja) | 2015-07-21 | 2023-03-08 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562195254P | 2015-07-21 | 2015-07-21 | |
US62/195,254 | 2015-07-21 | ||
PCT/US2016/043392 WO2017015490A1 (en) | 2015-07-21 | 2016-07-21 | T cells for expression of chimeric antigen receptors and other receptors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021101244A Division JP7242761B2 (ja) | 2015-07-21 | 2021-06-18 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018525982A JP2018525982A (ja) | 2018-09-13 |
JP6902018B2 true JP6902018B2 (ja) | 2021-07-14 |
Family
ID=57834724
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018502699A Active JP6902018B2 (ja) | 2015-07-21 | 2016-07-21 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
JP2021101244A Active JP7242761B2 (ja) | 2015-07-21 | 2021-06-18 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
JP2023035590A Pending JP2023076471A (ja) | 2015-07-21 | 2023-03-08 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021101244A Active JP7242761B2 (ja) | 2015-07-21 | 2021-06-18 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
JP2023035590A Pending JP2023076471A (ja) | 2015-07-21 | 2023-03-08 | キメラ抗原受容体及び他の受容体の発現に対するt細胞 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20190175648A1 (ja) |
EP (1) | EP3324984A4 (ja) |
JP (3) | JP6902018B2 (ja) |
CN (1) | CN108348550A (ja) |
AU (2) | AU2016297605A1 (ja) |
CA (1) | CA2992989A1 (ja) |
HK (1) | HK1256130A1 (ja) |
WO (1) | WO2017015490A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3704230A1 (en) * | 2017-11-01 | 2020-09-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
GB201800298D0 (en) | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
GB201803376D0 (en) * | 2018-03-01 | 2018-04-18 | Imperial Innovations Ltd | Transduction and expansion of cells |
CA3093810A1 (en) * | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
MX2021008652A (es) * | 2019-01-18 | 2021-10-26 | Janssen Biotech Inc | Receptores de antígenos quiméricos de gprc5d y células que los expresan. |
US20220249560A1 (en) | 2019-05-24 | 2022-08-11 | City Of Hope | Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies |
MX2022006365A (es) | 2019-11-26 | 2022-06-22 | Novartis Ag | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. |
WO2022040577A1 (en) | 2020-08-20 | 2022-02-24 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
US20230364138A1 (en) | 2020-11-23 | 2023-11-16 | City Of Hope | Engineered t cells for expression of chimeric anitgen receptors |
WO2022125837A1 (en) | 2020-12-09 | 2022-06-16 | City Of Hope | Compositions and uses of cd19 targeted chimeric antigen receptor modified immune cells |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2023019140A1 (en) | 2021-08-09 | 2023-02-16 | City Of Hope | Chimeric antigen receptor t cells targeting gd and oncolytic viruses for cancer therapy and treatment of hsv |
WO2023173116A1 (en) | 2022-03-10 | 2023-09-14 | City Of Hope | Membrane-bound il-12 for cellular immunotherapy |
WO2023201314A1 (en) | 2022-04-13 | 2023-10-19 | City Of Hope | Cmv-hiv specific chimeric antigen receptor t cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2713462C (en) * | 2008-01-29 | 2020-04-14 | Fred Hutchinson Cancer Research Center | Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity |
BR112013024395B1 (pt) * | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
RU2011130448A (ru) * | 2011-07-22 | 2013-01-27 | Зао "Евроген" | Методы и наборы для увеличения разнообразия т-клеток |
LT2884999T (lt) * | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
JP2016523102A (ja) * | 2013-06-24 | 2016-08-08 | アントフロゲネシス コーポレーション | T細胞を増殖させるための方法 |
-
2016
- 2016-07-21 CN CN201680053323.4A patent/CN108348550A/zh active Pending
- 2016-07-21 JP JP2018502699A patent/JP6902018B2/ja active Active
- 2016-07-21 US US15/746,212 patent/US20190175648A1/en active Pending
- 2016-07-21 WO PCT/US2016/043392 patent/WO2017015490A1/en active Application Filing
- 2016-07-21 EP EP16828557.5A patent/EP3324984A4/en active Pending
- 2016-07-21 AU AU2016297605A patent/AU2016297605A1/en not_active Abandoned
- 2016-07-21 CA CA2992989A patent/CA2992989A1/en active Pending
-
2018
- 2018-11-28 HK HK18115211.1A patent/HK1256130A1/zh unknown
-
2021
- 2021-06-18 JP JP2021101244A patent/JP7242761B2/ja active Active
-
2022
- 2022-12-12 AU AU2022287548A patent/AU2022287548A1/en active Pending
-
2023
- 2023-03-08 JP JP2023035590A patent/JP2023076471A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023076471A (ja) | 2023-06-01 |
CA2992989A1 (en) | 2017-01-26 |
EP3324984A1 (en) | 2018-05-30 |
CN108348550A (zh) | 2018-07-31 |
JP2018525982A (ja) | 2018-09-13 |
JP7242761B2 (ja) | 2023-03-20 |
AU2016297605A1 (en) | 2018-02-15 |
JP2021164461A (ja) | 2021-10-14 |
WO2017015490A1 (en) | 2017-01-26 |
US20190175648A1 (en) | 2019-06-13 |
EP3324984A4 (en) | 2019-03-27 |
HK1256130A1 (zh) | 2019-09-13 |
AU2022287548A1 (en) | 2023-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7242761B2 (ja) | キメラ抗原受容体及び他の受容体の発現に対するt細胞 | |
US20200095547A1 (en) | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors | |
US11111478B2 (en) | Methods of producing T memory stem cell populations | |
JP6799895B2 (ja) | TCRγδ+T細胞の生産方法 | |
JP5779090B2 (ja) | 新規に単離された細胞の治療組成物の操作および送達 | |
CN107002039B (zh) | 使用t细胞用于培养自然杀伤细胞的方法 | |
JP6422344B2 (ja) | 同種抗原反応性の制御性t細胞を増大させる方法 | |
JP7483087B2 (ja) | 造血幹細胞移植用の組成物および方法 | |
CN103620022A (zh) | Nk细胞的扩增方法 | |
KR102534472B1 (ko) | 케모카인 리셉터와 세포 접착 분자를 발현하는 cd3 음성 세포의 집단, 및 그 이용 그리고 그 제조 방법 | |
JP2015513403A5 (ja) | ||
JP2018526022A (ja) | 適応型の表現型を示すnk細胞ならびにその製造方法および使用方法 | |
CN110603320A (zh) | 高活性nk细胞及其应用 | |
JP5840857B2 (ja) | 細胞傷害性t細胞誘導用組成物 | |
CN113613723A (zh) | 包含nk细胞的细胞群体的制造方法 | |
JPWO2009145238A1 (ja) | 免疫調節剤及びその利用 | |
JPWO2012096376A1 (ja) | 制御性t細胞の製造方法 | |
US20220145252A1 (en) | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors | |
CN102596209A (zh) | 含有短暂性存活ctl的医药品组合物 | |
JP2023153286A (ja) | Nk細胞を含む細胞集団の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190719 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210330 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210520 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210618 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6902018 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |